Enzo Biochem’s Clinical Laboratory Named an In-Network Provider to the Fourth Largest National Insurer
April 17 2017 - 8:30AM
Business Wire
Enzo Biochem, Inc. (NYSE:ENZ) announced today that its Enzo
Clinical Laboratory subsidiary, a full-service clinical laboratory
with a specialty in women’s health, today reached an agreement with
the nation's fourth largest health insurer to become an in-network
provider serving all states with its advanced laboratory testing
services. Enzo Clinical Labs began offering in-network services to
their universe of 15 million of the insured participants on April
15, 2017.
“We are pleased to be contracted with an additional national
in-network health provider group and have already begun performing
services,” said Barry Weiner, Enzo President. “Enzo Clinical Labs
is focused on providing the highest standards of quality and care
for medical professionals and their patients, especially in today’s
fast growing realm of molecular diagnostics where we employ the
most advanced procedures and technology. We plan to expand our
in-network provider network as our business grows nationwide.
“The integrated strength of our two subsidiaries, Enzo Life
Sciences and Enzo Clinical Labs, has placed Enzo as a leading
provider of cost efficient and medically relevant assays and
reagents, and the platforms upon which they are utilized. These
applications allow for state of the art molecular diagnostics for
detecting a spectrum of diseases and providing vital clinical
information that could impact their treatments.
“Our strategy is driving Enzo to become a national reference
laboratory and technology developer with a vast array of highly
reliable products and services. Our advanced diagnostic
capabilities will now be available to many of the insurer’s plan
members throughout the U.S.”
A full list of Enzo in-network insurance partners can be found
at www.enzoclinicallabs.com.
About Enzo
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
Except for historical information, the matters discussed in this
news release may be considered "forward-looking" statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements include declarations regarding the intent,
belief or current expectations of the Company and its management,
including those related to cash flow, gross margins, revenues, and
expenses which are dependent on a number of factors outside of the
control of the Company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other
expenses, government regulations, litigation, and general business
conditions. See Risk Factors in the Company’s Form 10-K for the
fiscal year ended July 31, 2016. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that
could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of
developments occurring after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170417005454/en/
For Enzo Biochem, Inc.:Steve Anreder,
212-532-3232steven.anreder@anreder.comorCEOcast, Inc.Michael Wachs,
212-732-4300mwachs@ceocast.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Sep 2023 to Sep 2024